No Evidence of Moderated Impulsivity Following Administration of the IMPase Inhibitor Ebselen in Healthy Adults [0.03%]
健康成人施用内源性鸟苷酸环化酶配体后多巴胺能传递未发生变化
Matthew P G John,Luke Earnshaw,Nikhil Gauri Shankar et al.
Matthew P G John et al.
Objective: Impulsivity is a transdiagnostic risk factor for numerous health morbidities and is strongly associated with early relapse and poor treatment outcomes in addictions and mood-disorders. Lithium carbonate can be ...
Randomized Controlled Trial
Human psychopharmacology. 2026 May;41(3):e70040. DOI:10.1002/hup.70040 2026
Enhanced Cardiac Surveillance in Child Psychiatry: Role of Frontal QRS Angle During Atypical Antipsychotic Treatment [0.03%]
儿童精神病学中增强的心脏监测：非典型抗精神病治疗期间 frontal QRS 角的作用
Duygu Özge Asena,Duygu Ali,Dilli Gürkan Merve et al.
Duygu Özge Asena et al.
Introduction: Atypical antipsychotics are widely prescribed in child and adolescent psychiatry and are known to affect cardiac repolarization, most commonly reflected by QTc prolongation. However, QTc alone may not fully ...
Observational Study
Human psychopharmacology. 2026 May;41(3):e70042. DOI:10.1002/hup.70042 2026
Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [0.03%]
胰高血糖素样肽-1受体激动剂对心理幸福感和抑郁症状疗效的系统评价和 meta 分析
Tsung-Hsuan Hung,Chyi-Rong Chen,Chih-Wei Hsu et al.
Tsung-Hsuan Hung et al.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for metabolic disorders. Howeve, their effects on depressive symptoms and psychological well-being remain uncertain. ...
Meta-Analysis
Human psychopharmacology. 2026 May;41(3):e70041. DOI:10.1002/hup.70041 2026
Bupropion-Memantine Combination in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression [0.03%]
巴普品和美金刚联合治疗抑郁症及难治性抑郁的疗效观察
Juan Miguel Riestra,Yaxel Levin-Carrion,Roshan Sutar et al.
Juan Miguel Riestra et al.
Treatment-resistant depression (TRD) remains a formidable challenge in psychiatry, with nearly one-third of patients with major depressive disorder (MDD) failing to respond adequately to first-line pharmacological treatments. Pathophysiolog...
Comparison of Hip Fracture Risk Between Zolpidem and Zopiclone in Older Adults [0.03%]
唑吡坦与扎莱普隆导致老年人髋部骨折的风险比较研究
Shih-Wei Lai,Kuan-Fu Liao
Shih-Wei Lai
Objective: Zolpidem and zopiclone are widely prescribed hypnotics for older adults, yet their comparative safety regarding hip fracture risk remains unclear. This study aimed to compare the risk of hip fracture between zo...
Comparative Study
Human psychopharmacology. 2026 May;41(3):e70038. DOI:10.1002/hup.70038 2026
Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis-Application in a Real-World Setting [0.03%]
在精神病患者中开发体重增加的多基因风险评分及其在真实世界中的应用
Adrian Heald,Yasitha Illangasekera,Camila Marcelino Loureiro et al.
Adrian Heald et al.
Introduction: Genetic factors are thought to play an important role in antipsychotic-induced weight gain (AIWG). Polygenic risk scores (PRS) could provide a measure of genetic predisposition to antipsychotic drug induced ...
Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders: A Systematic Review and Meta-Analysis of Current Evidence [0.03%]
米塔扎pine在焦虑和创伤相关障碍中的临床潜力：当前证据的系统评价和meta分析
Claudio Caiazza,Vito Rago,Niccolò Solini et al.
Claudio Caiazza et al.
Objective: Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with sedative features that may be advantageous for anxiety and trauma-related disorders, yet its role remains unclear. ...
Evaluation of Depression, Anxiety, and Sleep Quality in Patients With Acne Vulgaris Receiving Isotretinoin Treatment [0.03%]
异维A酸治疗痤疮患者抑郁、焦虑及睡眠质量的评估
Candan Celik,Mehmet Semih Celik
Candan Celik
Background and objective: Isotretinoin is a systemic agent widely used in the treatment of severe acne vulgaris. Previous studies have reported that isotretinoin use may be associated with depression, anxiety, and sleep d...
Comparison of Side Effects Between 3-Monthly and 1-Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia [0.03%]
三个月一次的帕利哌酮酯与一个月一次的帕利哌酮酯在精神分裂症患者中副作用的对比研究
Erkan Kuru,Ilker Ozdemir,Bengu Yucens et al.
Erkan Kuru et al.
Background: The paliperidone palmitate 3-month (PP3M) formulation offers an extended dosing interval compared to the 1-month (PP1M) formulation. However, data on the comparative side effect profiles of PP1M versus PP3M in...
Comparative Study
Human psychopharmacology. 2026 Jan;41(1):e70033. DOI:10.1002/hup.70033 2026